Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications.

ABSTRACT: Around 80-90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient's response to androgen ablation therapy is variable, and 20-30% of PCa cases become castration resistant (CRPCa). Several mechanisms can guide treatment resistance to anti-AR molecules. In this regard, AR-dependent and -independent resistance mechanisms can be distinguished within the AR pathway. In this article, we investigate the multitude of AR signaling aspects, encompassing the biological structure of AR, current AR-targeted therapies, mechanisms driving resistance to AR, and AR crosstalk with other pathways,

SUBMITTER: Aurilio G 

PROVIDER: S-EPMC7763510 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature